Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
H.J. Cutuli
OpenAlex ID:
A5159559048
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy
2026
·
D.Y.C. Heng
, M. Schmidinger
, et al.
·
Annals of Oncology
·
2
PDF
Show more works
View as search
Works count:
1
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type
